cc-10q_20170630.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2017

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number 001-36794

The Chemours Company

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

46-4845564

(State or other Jurisdiction of

Incorporation or Organization)

(I.R.S. Employer

Identification No.)

1007 Market Street, Wilmington, Delaware 19899

(Address of Principal Executive Offices)

(302) 773-1000

(Registrant’s Telephone Number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that registrant was required to submit and post such files). Yes ☒ No 

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.  (Check one):

 

Large Accelerated Filer 

Accelerated Filer 

Non-Accelerated Filer 

Smaller reporting company 

 

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

Indicate by check mark whether the Registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes No 

The Registrant had 184,800,961 shares of common stock, $0.01 par value, outstanding at July 31, 2017.

 

 

 

 


 

The Chemours Company

Table of Contents

 

 

 

Page

Part I

Financial Information

 

Item 1.

Interim Consolidated Financial Statements

 

 

Interim Consolidated Statements of Operations (Unaudited)

2

 

Interim Consolidated Statements of Comprehensive Income (Loss) (Unaudited)

3

 

Interim Consolidated Balance Sheets

4

 

Interim Consolidated Statements of Stockholders’ Equity (Unaudited)

5

 

Interim Consolidated Statements of Cash Flows (Unaudited)

6

 

Notes to the Interim Consolidated Financial Statements (Unaudited)

7

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

30

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

44

Item 4.

Controls and Procedures

45

 

 

 

Part II

Other Information

 

Item 1.

Legal Proceedings

45

Item 1A.

Risk Factors

46

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

46

Item 3.

Defaults Upon Senior Securities

46

Item 4.

Mine Safety Disclosures

46

Item 5.

Other Information

46

Item 6.

Exhibits

46

 

Signature

 

 

47

 

Exhibit Index

 

 

48

 

 

 

1


 

PART I.  FINANCIAL INFORMATION

Item 1.

INTERIM CONSOLIDATED FINANCIAL STATEMENTS

The Chemours Company

Interim Consolidated Statements of Operations (Unaudited)

(Dollars in millions, except per share amounts)

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2017

 

 

2016

 

 

2017

 

 

2016

 

Net sales

 

$

1,588

 

 

$

1,383

 

 

$

3,024

 

 

$

2,680

 

Cost of goods sold

 

 

1,147

 

 

 

1,116

 

 

 

2,225

 

 

 

2,212

 

Gross profit

 

 

441

 

 

 

267

 

 

 

799

 

 

 

468

 

Selling, general and administrative expense

 

 

157

 

 

 

174

 

 

 

301

 

 

 

307

 

Research and development expense

 

 

21

 

 

 

17

 

 

 

40

 

 

 

40

 

Restructuring and asset-related charges, net

 

 

6

 

 

 

67

 

 

 

18

 

 

 

85

 

Total expenses

 

 

184

 

 

 

258

 

 

 

359

 

 

 

432

 

Equity in earnings of affiliates

 

 

10

 

 

 

4

 

 

 

17

 

 

 

9

 

Interest expense, net

 

 

(55

)

 

 

(50

)

 

 

(106

)

 

 

(106

)

Other income (expense), net

 

 

13

 

 

 

(4

)

 

 

48

 

 

 

89

 

Income (loss) before income taxes

 

 

225

 

 

 

(41

)

 

 

399

 

 

 

28

 

Provision for (benefit from) income taxes

 

 

64

 

 

 

(23

)

 

 

87

 

 

 

(5

)

Net income (loss)

 

 

161

 

 

 

(18

)

 

 

312

 

 

 

33

 

Less: Net income attributable to non-controlling interests

 

 

 

 

 

 

 

 

1

 

 

 

 

Net income (loss) attributable to Chemours

 

$

161

 

 

$

(18

)

 

$

311

 

 

$

33

 

Per share data

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic earnings (loss) per share of common stock

 

$

0.87

 

 

$

(0.10

)

 

$

1.69

 

 

$

0.18

 

Diluted earnings (loss) per share of common stock

 

$

0.84

 

 

$

(0.10

)

 

$

1.64

 

 

$

0.18

 

Dividends per share of common stock

 

$

0.03

 

 

$

0.03

 

 

$

0.06

 

 

$

0.06

 

 

See accompanying notes to the interim consolidated financial statements.

2


 

The Chemours Company

Interim Consolidated Statements of Comprehensive Income (Loss) (Unaudited)

(Dollars in millions)

 

 

 

Three Months Ended June 30,

 

 

 

2017

 

 

2016

 

 

 

Pre-Tax

 

 

Tax

 

 

After-Tax

 

 

Pre-Tax

 

 

Tax

 

 

After-Tax

 

Net income (loss)

 

$

225

 

 

$

(64

)

 

$

161

 

 

$

(41

)

 

$

23

 

 

$

(18

)

Other comprehensive income (loss):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized (loss) gain on net

   investment hedge

 

 

(40

)

 

 

10

 

 

 

(30

)

 

 

4

 

 

 

 

 

 

4

 

Cumulative translation

   adjustments

 

 

84

 

 

 

 

 

 

84

 

 

 

(9

)

 

 

 

 

 

(9

)

Defined benefit plans:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

(7

)

 

1

 

 

 

(6

)

Effect of foreign

   exchange rates

 

 

(15

)

 

 

3

 

 

 

(12

)

 

 

4

 

 

 

 

 

 

4

 

Reclassifications to net

   income (loss):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of actuarial loss

 

 

5

 

 

 

(1

)

 

 

4

 

 

 

7

 

 

 

(2

)

 

 

5

 

Curtailment gain

 

 

 

 

 

 

 

 

 

 

 

(2

)

 

 

 

 

 

(2

)

Defined benefit plans, net

 

 

(10

)

 

 

2

 

 

 

(8

)

 

 

2

 

 

 

(1

)

 

 

1

 

Other comprehensive income (loss)

 

 

34

 

 

 

12

 

 

 

46

 

 

 

(3

)

 

 

(1

)

 

 

(4

)

Comprehensive income (loss)

 

 

259

 

 

 

(52

)

 

 

207

 

 

 

(44

)

 

 

22

 

 

 

(22

)

Less: Comprehensive income attributable to non-controlling interests

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Comprehensive income (loss) attributable to Chemours

 

$

259

 

 

$

(52

)

 

$

207

 

 

$

(44

)

 

$

22

 

 

$

(22

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Six Months Ended June 30,

 

 

 

2017

 

 

2016

 

 

 

Pre-Tax

 

 

Tax

 

 

After-Tax

 

 

Pre-Tax

 

 

Tax

 

 

After-Tax

 

Net income

 

$

399

 

 

$

(87

)

 

$

312

 

 

$

28

 

 

$

5

 

 

$

33

 

Other comprehensive income (loss):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized loss on net

   investment hedge

 

 

(50

)

 

 

10

 

 

 

(40

)

 

 

(3

)

 

 

 

 

 

(3

)

Cumulative translation

   adjustments

 

 

189

 

 

 

 

 

 

189

 

 

 

10

 

 

 

 

 

 

10

 

Defined benefit plans:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

(7

)

 

1

 

 

 

(6

)

Effect of foreign

   exchange rates

 

 

(27

)

 

 

6

 

 

 

(21

)

 

 

(1

)

 

 

1

 

 

 

 

Reclassifications to net

   income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of prior service gain

 

 

 

 

 

 

 

 

 

 

 

(1

)

 

 

 

 

 

(1

)

Amortization of actuarial loss

 

 

10

 

 

 

(2

)

 

 

8

 

 

 

11

 

 

 

(3

)

 

 

8

 

Curtailment gain

 

 

 

 

 

 

 

 

 

 

 

(2

)

 

 

1

 

 

 

(1

)

Defined benefit plans, net

 

 

(17

)

 

 

4

 

 

 

(13

)

 

 

 

 

 

 

 

 

 

Other comprehensive income

 

 

122

 

 

 

14

 

 

 

136

 

 

 

7

 

 

 

 

 

 

7

 

Comprehensive income

 

 

521

 

 

 

(73

)

 

 

448

 

 

 

35

 

 

 

5

 

 

 

40

 

Less: Comprehensive income attributable to non-controlling interests

 

 

1

 

 

 

 

 

 

1

 

 

 

 

 

 

 

 

 

 

Comprehensive income attributable to Chemours

 

$

520

 

 

$

(73

)

 

$

447

 

 

$

35

 

 

$

5

 

 

$

40

 

 

See accompanying notes to the interim consolidated financial statements.

3


 

The Chemours Company

Interim Consolidated Balance Sheets

(Dollars in millions, except per share amounts)

 

 

 

(Unaudited)

 

 

 

 

 

 

 

June 30,

 

 

December 31,

 

 

 

2017

 

 

2016

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

1,529

 

 

$

902

 

Accounts and notes receivable - trade, net

 

 

994

 

 

 

807

 

Inventories

 

 

848

 

 

 

767

 

Prepaid expenses and other

 

 

69

 

 

 

77

 

Total current assets

 

 

3,440

 

 

 

2,553

 

Property, plant and equipment

 

 

8,288

 

 

 

7,997

 

Less: Accumulated depreciation

 

 

(5,386

)

 

 

(5,213

)

Property, plant and equipment, net

 

 

2,902

 

 

 

2,784

 

Goodwill and other intangible assets, net

 

 

168

 

 

 

170

 

Investments in affiliates

 

 

158

 

 

 

136

 

Other assets

 

 

384

 

 

 

417

 

Total assets

 

$

7,052

 

 

$

6,060

 

Liabilities and equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

985

 

 

$

884

 

Current maturities of long-term debt

 

 

14

 

 

 

15

 

Other accrued liabilities

 

 

751

 

 

 

872

 

Total current liabilities

 

 

1,750

 

 

 

1,771

 

Long-term debt, net

 

 

4,056

 

 

 

3,529

 

Deferred income taxes

 

 

159

 

 

 

132

 

Other liabilities

 

 

515

 

 

 

524

 

Total liabilities

 

 

6,480

 

 

 

5,956

 

Commitments and contingent liabilities

 

 

 

 

 

 

 

 

Equity

 

 

 

 

 

 

 

 

Common stock (par value $0.01 per share; 810,000,000 shares authorized)

 

 

2

 

 

 

2

 

Additional paid-in capital

 

 

820

 

 

 

789

 

Retained earnings (accumulated deficit)

 

 

186

 

 

 

(114

)

Accumulated other comprehensive loss

 

 

(441

)

 

 

(577

)

Total Chemours stockholders’ equity

 

 

567

 

 

 

100

 

Non-controlling interests

 

 

5

 

 

 

4

 

Total equity

 

 

572

 

 

 

104

 

Total liabilities and equity

 

$

7,052

 

 

$

6,060

 

 

See accompanying notes to the interim consolidated financial statements.

4


 

The Chemours Company

Interim Consolidated Statements of Stockholders’ Equity (Unaudited)

(Dollars in millions)

 

 

 

Common Stock

 

 

Additional

Paid-In

 

 

Accumulated

Other

Comprehensive

 

 

(Accumulated Deficit) Retained

 

 

Non-controlling

 

 

 

 

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

(Loss) Income

 

 

Earnings

 

 

Interests

 

 

Total

 

Balance at

   January 1, 2016

 

 

181,069,751

 

 

$

2

 

 

$

775

 

 

$

(536

)

 

$

(115

)

 

$

4

 

 

$

130

 

Net income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

33

 

 

 

 

 

 

33

 

Common stock issued -   compensation plans

 

 

421,675

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Dividends

 

 

 

 

 

 

 

 

(11

)

 

 

 

 

 

 

 

 

 

 

 

(11

)

Other comprehensive income

 

 

 

 

 

 

 

 

 

 

 

7

 

 

 

 

 

 

 

 

 

7

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

10

 

 

 

 

 

 

 

 

 

 

 

 

10

 

Balance at

   June 30, 2016

 

 

181,491,426

 

 

$

2

 

 

$

774

 

 

$

(529

)

 

$

(82

)

 

$

4

 

 

$

169

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at

   January 1, 2017

 

 

182,600,533

 

 

$

2

 

 

$

789

 

 

$

(577

)

 

$

(114

)

 

$

4

 

 

$

104

 

Net income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

311

 

 

 

1

 

 

 

312

 

Common stock issued - compensation plans

 

 

461,754

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Dividends

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(11

)

 

 

 

 

 

(11

)

Other comprehensive income

 

 

 

 

 

 

 

 

 

 

 

136

 

 

 

 

 

 

 

 

 

136

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

15

 

 

 

 

 

 

 

 

 

 

 

 

15

 

Cancellation of unissued stock awards

 

 

 

 

 

 

 

 

(10

)

 

 

 

 

 

 

 

 

 

 

 

(10

)

Exercise of stock options

 

 

1,628,850

 

 

 

 

 

 

26

 

 

 

 

 

 

 

 

 

 

 

 

26

 

Balance at

   June 30, 2017

 

 

184,691,137

 

 

$

2

 

 

$

820

 

 

$

(441

)

 

$

186

 

 

$

5

 

 

$

572

 

 

See accompanying notes to the interim consolidated financial statements.

5


 

The Chemours Company

Interim Consolidated Statements of Cash Flows (Unaudited)

(Dollars in millions)

 

 

 

Six Months Ended June 30,

 

 

 

2017

 

 

2016

 

Operating activities

 

 

 

 

 

 

 

 

Net income

 

$

312

 

 

$

33

 

Adjustments to reconcile net income to cash provided by operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

142

 

 

 

139

 

Amortization of deferred financing costs and issuance discount

 

 

7

 

 

 

11

 

Gain on sale of assets and businesses

 

 

(14

)

 

 

(88

)

Equity in earnings of affiliates

 

 

(17

)

 

 

(9

)

Deferred tax provision (benefit)

 

 

38

 

 

 

(36

)

Asset-related charges

 

 

2

 

 

 

63

 

Other operating charges and credits, net

 

 

13

 

 

 

14

 

(Increase) decrease in operating assets:

 

 

 

 

 

 

 

 

Accounts and notes receivable - trade, net

 

 

(170

)

 

 

(92

)

Inventories and other operating assets

 

 

(43

)

 

 

85

 

(Decrease) increase in operating liabilities:

 

 

 

 

 

 

 

 

Accounts payable and other operating liabilities

 

 

(46

)

 

 

6

 

Cash provided by operating activities

 

 

224

 

 

 

126

 

Investing activities

 

 

 

 

 

 

 

 

Purchases of property, plant and equipment

 

 

(138

)

 

 

(168

)

Proceeds from sales of assets and businesses, net

 

 

38

 

 

 

150

 

Foreign exchange contract settlements, net

 

 

2

 

 

 

 

Cash used for investing activities

 

 

(98

)

 

 

(18

)

Financing activities

 

 

 

 

 

 

 

 

Proceeds from issuance of debt, net

 

 

494

 

 

 

 

Debt repayments

 

 

(20

)

 

 

(95

)

Dividends paid

 

 

(11

)

 

 

(11

)

Deferred financing fees

 

 

(6

)

 

 

(2

)

Proceeds from exercised stock options

 

 

26

 

 

 

 

Cash provided by (used for) financing activities

 

 

483

 

 

 

(108

)

Effect of exchange rate changes on cash and cash equivalents

 

 

18

 

 

 

17

 

Increase in cash and cash equivalents

 

 

627

 

 

 

17

 

Cash and cash equivalents at beginning of the period

 

 

902

 

 

 

366

 

Cash and cash equivalents at end of the period

 

$

1,529

 

 

$

383

 

Non-cash investing activities

 

 

 

 

 

 

 

 

Change in property, plant and equipment included in accounts payable

 

$

(5

)

 

$

10

 

 

 

 

See accompanying notes to the interim consolidated financial statements.

6


 

The Chemours Company

Notes to the Interim Consolidated Financial Statements (Unaudited)

(Dollars in millions, except per share amounts)

Note 1. Basis of Presentation

The accompanying interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles (GAAP) in the United States of America (U.S.) for interim financial information.  In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the results for interim periods have been included.  Results for interim periods should not be considered indicative of results for a full year and the year-end consolidated balance sheet does not include all disclosures required by U.S. GAAP. As such, these interim consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2016.

Unless the context otherwise requires, references herein to “The Chemours Company”, “Chemours”, “the Company”, “our company”, “we”, “us” and “our” refer to The Chemours Company and its consolidated subsidiaries.  References herein to “DuPont” refer to E.I. du Pont de Nemours and Company, a Delaware corporation, and its consolidated subsidiaries (other than Chemours and its consolidated subsidiaries), unless the context otherwise requires.

Note 2. Recent Accounting Pronouncements

Accounting Guidance Not Yet Adopted

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, “Revenue from Contracts with Customers (Topic 606).”  The objective of this standard is to remove inconsistent practices with regard to revenue recognition between U.S. GAAP and International Financial Reporting Standards. The standard intends to improve comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets.  Subsequent to the issuance of ASU No. 2014-09, the FASB issued multiple clarifying updates in connection with Topic 606.  The provisions of ASU No. 2014-09 and related updates will be effective for interim and annual periods beginning after December 15, 2017, with early adoption permitted for annual periods beginning after December 15, 2016.  The Company plans to adopt the standard as of January 1, 2018 under the modified retrospective transition method.

The Company’s project plan includes a three-phase approach to implementing this standard update. Phase one, the assessment phase, was completed in the first quarter of 2017.  In this initial phase, the Company conducted internal surveys of its businesses, held revenue recognition workshops with sales and business unit finance leadership and reviewed a representative sample of revenue arrangements across all businesses to initially identify a set of applicable qualitative revenue recognition changes related to the new standard.  The Company is currently finalizing phase two of the project, which includes establishing and documenting key accounting positions, assessing new disclosure requirements, business process and control impacts and beginning to determine initial quantitative impacts resulting from the new standard.  Phase three’s objectives will comprise of effectively implementing the new standard and embedding the new accounting treatment into the Company’s business processes and controls to support financial reporting requirements.  Phase three is expected to be completed in the fourth quarter of 2017.

The Company is still evaluating the impact that the new standard will have on the Company’s consolidated financial statements and will be unable to quantify its impact until phase three of the project has been completed.

In August 2016, the FASB issued various updates to ASU No. 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments”, which clarifies and amends the presentation and classification of certain cash receipts and cash payments in the statement of cash flows.  The guidance is effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years.  The amendments should be applied using a retrospective transition method (unless impractical to do so) for each period presented and earlier application is permitted.  Chemours is currently evaluating the impact of adopting this guidance, but does not expect the adoption will have a significant impact on its cash flows.

In March 2017, the FASB issued ASU No. 2017-07, “Compensation - Retirement Benefits (Topic 715)”, which requires that employers offering their employees defined benefit pension plans disaggregate the service cost component from the other components of net benefit cost.  The amendments also provide explicit guidance on how to present the service cost component and the other components of net benefit cost in the income statement and allow only the service cost component of net benefit cost to be eligible for capitalization.  The guidance is effective for public business entities for annual periods beginning after December 15, 2017, as well as interim periods within those annual periods.  The amendments in this update should be applied retrospectively for the presentation of the service cost component and the other components of net periodic pension cost and net periodic post-retirement benefit cost in the

7


The Chemours Company

Notes to the Interim Consolidated Financial Statements (Unaudited)

(Dollars in millions, except per share amounts)

 

income statement and prospectively for the capitalization of the service cost component of net periodic pension cost and net periodic post-retirement benefit in assets.  Early adoption is permitted within the first interim period of an annual period for which financial statements have not been issued or made available for issuance.  Chemours is currently evaluating the impact of adopting this guidance, but does not expect the adoption will have a significant impact on its results of operations.  The adoption is not expected to have any impact on the Company’s financial position or cash flows.

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)”, which supersedes the leases requirements in Topic 840.  The core principle of Topic 842 is that a lessee should recognize on the balance sheet the lease assets and lease liabilities that arise from all lease arrangements with terms greater than 12 months.  Recognition of these lease assets and lease liabilities represents an improvement over previous U.S. GAAP, which did not require lease assets and lease liabilities to be recognized for operating leases.  Qualitative disclosures along with specific quantitative disclosures will be required to provide enough information to supplement the amounts recorded in the financial statements so that users can understand more about the nature of an entity’s leasing activities.  Lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach, which includes a number of optional practical expedients that entities may elect to apply.  The amendments in this update are effective for the Company’s fiscal year beginning January 1, 2019, including interim periods within that fiscal year.  Early application of the amendments in this update is permitted for all entities.  At adoption, the Company will recognize a right-of-use asset and a lease liability initially measured at the present value of its operating lease payments.  The Company is currently evaluating the other impacts of adopting this guidance on its financial position, results of operations and cash flows.

Recently Adopted Accounting Guidance

In March 2016, the FASB issued ASU No. 2016-09, “Compensation - Stock Compensation (Topic 718).”  The update sets forth areas for simplification within several aspects of the accounting for shared-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows.  The amendments in this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016.  Chemours adopted this guidance effective January 1, 2017, and the adoption did not have a significant impact on the Company’s financial position, results of operations and cash flows except for the impact of windfall income tax benefits on share-based payments.  We expect the guidance will cause volatility in the Company’s income tax rates going forward.  As of the adoption date, there were no windfall tax benefits from prior periods recognized; therefore, prior period adjustments were not required under a modified retrospective basis.  For the three and six months ended June 30, 2017, Chemours recognized approximately $3 and $13 of windfall tax benefits, respectively, primarily from significant options exercised and restricted stock units (RSUs) vested, which were included in the provision for income taxes in the consolidated statements of operations.

In January 2017, the FASB issued ASU No. 2017-04, “Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment”, which eliminates the requirement to determine the fair value of individual assets and liabilities of a reporting unit to measure goodwill impairment. Under the amendments, goodwill impairment testing will be performed by comparing the fair value of the reporting unit with its carrying amount and recognizing an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, but not to exceed the total amount of goodwill allocated to the reporting unit. The guidance is effective for annual and interim goodwill impairment tests in fiscal years beginning after December 15, 2019, and should be applied on a prospective basis. Early adoption is permitted for annual or interim goodwill impairment testing performed after January 1, 2017. The Company has adopted this guidance and will implement its provisions for interim and annual goodwill impairment tests performed prospectively.  The Company does not expect the adoption of this guidance will have a significant impact on its financial position, results of operations or cash flows.

In May 2017, the FASB issued ASU No. 2017-09, “Compensation - Stock Compensation (Topic 718):  Scope of Modification Accounting”, which provides clarity and reduces both diversity in practice and cost and complexity when applying the guidance in Topic 718 to a change in the terms or conditions of a share-based payment award.  Pursuant to this update, modification accounting is required to be applied to changes in the terms and conditions of a share-based payment award unless all of the following criteria remain unchanged before and after the award is modified:  the fair value of the award; the vesting conditions of the award; and the classification of the award as an equity instrument or a liability instrument.  The amendments in this update are effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017, and are to be applied prospectively to an award modified on or after the adoption date.  Early adoption, including adoption in any interim period, is permitted for public business entities for reporting periods for which financial statements have not yet been issued.  The Company has adopted this guidance and will implement its provisions prospectively for changes in the terms and conditions of share-based payment awards.  The Company does not expect the adoption of this guidance will have a significant impact on its financial position, results of operations or cash flows.

8


The Chemours Company

Notes to the Interim Consolidated Financial Statements (Unaudited)

(Dollars in millions, except per share amounts)

 

Note 3. Restructuring and Asset-Related Charges, Net

For the three and six months ended June 30, 2017 and 2016, Chemours recorded charges for restructuring and asset-related charges as follows:

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2017

 

 

2016

 

 

2017

 

 

2016

 

Restructuring-related charges:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Employee separation (credits) charges

 

$